Reminder Trial Finds Early Administration of Eplerenone in Patients with Acute Stemi Improves Cardiovascular Outcomes
Sunday, 10 March 2013 14:33
SAN FRANCISCO, March 10, 2013
The REMINDER trial, presented on Sunday at the American College of Cardiology 2013 Scientific Sessions, revealed that the addition of eplerenone to standard therapy within 24 hours of symptom onset improves outcomes of patients with acute STEMI without evidence of heart failure.
“The benefit of eplerenone in the acute phase is very significant,” states Barbara Fletcher, RN, MN, FAHA, FPCNA, FAAN from the University of North Florida, Jacksonville and incoming president-elect on the Preventive Cardiovascular Nurses Association (PCNA) board of directors.
“The impact in post acute phase will need further investigation, but could be promising and impact clinical practice by nurses.”
Contact: Abby Despins, 920-606-2115, email@example.com